117 results about "Cell survival" patented technology

The invention discloses a construction method of a microplastic toxicity prediction model based on transcriptomics and a QSAR (Quantitative Synthetic Aperture Radar) model, which comprises the following steps: measuring actual observation values of cell survival rates of different microplastic samples after contamination and changes of genes in the cells, and screening out the genes as specific genes; selecting a physicochemical descriptor and then determining a gene expression descriptor of the specific gene; establishing a training set and a test set; a plurality of machine learning algorithms are utilized to construct QSAR models respectively, and an optimal QSAR model is selected according to a performance evaluation result; and carrying out performance verification on the optimal QSAR model, and screening out a microplastic toxicity prediction range suitable for the optimal QSAR model. The construction method of the microplastic toxicity prediction model can realize reliable prediction of toxicity, and can effectively support safety evaluation and biotoxicity mechanism research of microplastics.

The invention discloses an alpha nuclide drug in-vitro cellular response prediction method and system based on multi-module mathematical modeling and a medium, and the method comprises the steps: constructing a basic parameter input module, a pharmacokinetic prediction module, a cell absorbed dose calculation module and a biological effect prediction module which are connected in sequence; a three-compartment dynamical model and a micro-dose learning point kernel convolution and DNA damage repair dynamical model are integrated, and full-chain and quantitative simulation from drug distribution, microscopic energy deposition to cell survival is achieved. The method overcomes the defects that an existing empirical model cannot accurately reflect the high LET characteristic of alpha particles, neglects the bystander effect and repair dynamics and the like, and the prediction precision is remarkably improved. According to the method, the curative effects of different drugs, cell lines and dosage schemes can be quickly simulated on a computer, the research and development cost and period are greatly reduced, and an efficient theoretical tool is provided for new drug screening and dosage optimization.

The invention is applicable to the technical field of hydrogel, and provides dynamic cross-linked hydrogel and a preparation method and application thereof, and the preparation method comprises the following steps: cross-linking oxidized dextran and carboxymethyl chitosan containing phenylboronic acid modification groups; glucanase is added before the hydrogel is formed, and calcium peroxide nanoparticles coated with polydopamine are introduced; wherein the mass concentration of the oxidized dextran is 2-10% w / v, the mass concentration of the carboxymethyl chitosan containing the phenylboronic acid modified group is 2% w / v, the concentration of the glucanase is 10-100 U, and the concentration of the calcium peroxide nanoparticles coated with the polydopamine is 0.1-1% w / v. The hydrogel disclosed by the invention shows good cell compatibility, angiogenesis promoting capability and bioactivity for promoting dental pulp regeneration in multiple in-vitro and in-vivo experiments, is suitable for tissue engineering fields such as dental pulp injury repair and the like, and effectively solves the technical problem that conventional hydrogel is insufficient in cell survival support in three-dimensional culture and the like.

The present disclosure relates to methods of determining percentage viability of a cell composition comprising cell aggregates. Such methods may include providing a first aliquot of cells and a second aliquot of cells, wherein the first aliquot of cells and the second aliquot of cells have about the same concentration of cells, measuring a total number of live cells in the first aliquot of cells; measuring a total number of cells in the second aliquot of cells, and determining the percentage viability of the cell composition as a ratio between the total number of live cells in the first aliquot of cells and the total number cells in the second aliquot of cells.

The invention discloses application of lycium barbarum polysaccharide in preparation of a medicine for inhibiting methylamphetamine-induced nerve injury, and relates to the technical field of biological medicines. It is found and proved that lycium barbarum polysaccharide can inhibit methylamphetamine-induced nerve injury, and the effect is remarkable. From the aspect of cell survival, the survival rate of the microglial cells pretreated by the lycium barbarum polysaccharide after METH stimulation is obviously improved. In the molecular mechanism, the lycium barbarum polysaccharide can effectively lower the protein expression level of the METH-induced pyroptosis marker, the content of inflammatory factors IL-1beta and IL-18 can be reduced, and the release of lactic dehydrogenase is reduced. The result shows that the lycium barbarum polysaccharide can alleviate inflammatory response by inhibiting NLRP3 / ASC pathway mediated microglial cell pyroptosis, thereby inhibiting METH-induced nerve injury. The invention provides a new direction for developing METH neurotoxicity intervention medicines.

The invention provides a marker for diagnosing and treating radiodermatitis and application of the marker. The relation between SENP5 and radiodermatitis is researched for the first time, it is found that SENP5 is in positive correlation with occurrence and development of radiodermatitis, an SENP5 overexpression group shows better radiation resistance, skin cells are protected, and damage caused by radiation is relieved. The SENP5 is mainly used for promoting DNA damage repair by mediating an HR repair pathway. Besides, the SENP5 knocked-down cell line is successfully constructed by designing shRNA for specifically knocking down the SENP5 expression level, and it is proved that after SENP5 knocked-down skin cells are irradiated by 60Co rays, the cell survival level is lowered, the homologous recombination repair pathway is obviously inhibited, the NF-kappa B pathway is obviously activated, and the inflammation level is improved. Therefore, SENP5 is represented as an anti-radiation gene in skin cells, and SENP5 can be used as a biomarker of radiodermatitis for early diagnosis of radiodermatitis and targeted preparation of drugs for radiodermatitis.

The invention belongs to the field of biological medicine, and discloses a membrane binding type IL7 fusion protein, an engineered immune cell for expressing the membrane binding type IL7 fusion protein and application of the membrane binding type IL7 fusion protein. The fusion protein comprises an IL7 region and a transmembrane domain and can be expressed on a cell membrane, the tumor cell killing ability and the T cell survival ability of T cells expressing the fusion protein are both enhanced, and the aims of improving the tumor immune cell treatment effect and reducing the toxic and side effects are achieved. Particularly, the IL7 fusion protein anchors and expresses IL7 on the surface of a cell through transmembrane domains such as CD80 or PD-L1 and the like, so that (1) immune cells can be accurately regulated and controlled, the possibility that an excessive IL7 signal possibly causes autoimmune response or aggravates CRS is reduced, and the safety of the IL7 to immune cells such as T cells and the like is enhanced; (2) the half-life period of IL7 is prolonged, and the anti-tumor effect of adoptive immune cells is enhanced; and (3) the transmembrane fragment is linked with the IL7 through a hinge region of the flexible linker G4S, CD80 or PD-L1, so that the flexibility of the IL7 is enhanced, and the proliferation and killing functions of the IL7 on T cells are enhanced.

The invention discloses siRNA capable of knocking down Pr18a9 gene expression and application of the siRNA, and relates to the technical field of biological medicine. The invention provides a positive-sense strand sequence and an antisense strand sequence of the siRNA, and the siRNA is used for preparing a preparation for promoting Schwann cell survival. According to the invention, the Prl8a9 gene of SCs is knocked down by virtue of a small interfering RNA technology; by improving the proliferation and migration capabilities of the Schwann cells, the apoptosis rate of the Schwann cells is reduced, and the survival rate of the Schwann cells is further improved. Meanwhile, a transcriptome sequencing technology is applied, key genes and pathways of Schwann cells treated by siPr18a9 are deeply excavated, and a theoretical support is provided for research on a repair mechanism after peripheral nerve injury.

The invention belongs to the technical field of medical detection, and particularly relates to a method for detecting killing activity of immune cells, a product and application. Target cells are subjected to fluorescence labeling through fluorescence labeling (such as carboxyl fluorescein diacetate succinimide ester, CFSE), and then the intensity change of fluorescence signals in a target cell population is quantitatively analyzed by utilizing the high-sensitivity detection characteristic of flow cytometry. Based on the correlation between the fluorescence signal intensity and the cell survival state, establishing a mathematical model to calculate the relative survival rate of the cells. The detection method provided by the invention is simple and convenient in operation flow, and sample preparation can be completed only by single dyeing; and the detection process is rapid, the experiment cost is low, and the kit has wide applicability and important clinical transformation value in the application level.

The present application relates to the technical field of genetic engineering, and specifically discloses a Chlamydomonas reinhardtii SnRK2.7 gene and application thereof in adaptation to osmotic stress and maintenance of cell survival. The present application first discloses SnRK2.7 the key biological function of the gene in maintaining Chlamydomonas cell homeostasis. By knocking out the gene through CRISPR / Cas9 gene editing technology and adopting an expression frame driven by an endogenous promoter for genetic back complementation, it is confirmed that SnRK2.7 the gene positively regulates cell osmotic stress tolerance and maintains cell long-term survival. In addition, the present application first discovers that the SnRK2.7 protein is specifically located in the Chlamydomonas expansion vesicle, which provides direct spatial evidence for the cell function. The above discovery not only expands the understanding of the osmotic stress signal transduction mechanism of Chlamydomonas, but also provides a new gene target and research tool for the improvement of microalgae stress adaptability, and has important basic research value and biological technology application potential.

The invention belongs to the technical field of biological medicine, and particularly relates to a gene-edited immune cell and application thereof. The invention provides a composition. The composition comprises a cytokine and a chemokine receptor, the amplification and / or survival ability of cells containing or expressing the composition is enhanced, and the composition has a synergistic effect in promoting the survival and / or proliferation of the cells.

The invention provides an application of OGA as an inhibition target in preparation of drugs for treating GBC, and relates to the technical field of biomedicine.According to a specific verification test, it is found that GBC cells transfer OGA to neurons through EVs, so that glycosylation of RIPK1 is inhibited, phosphorylation and activation of RIPK1 are promoted, and finally neuronal necroptosis is induced. RIPK1 is a core factor for regulating and controlling cell survival, inflammatory response and programmed death, and is activated through a compound IIb pathway under the action of exogenous OGA. EV-induced invasion and necroptosis can be remarkably inhibited through neuron OGA knock-down, so that the aim of treating GBC is achieved.

Methods are provided for generating unlimited immune cells with increased lifespan and high proliferation rate by modifying them to express BCL6 and genes that promote cell survival. Further methods are provided for generating and using said unlimited immune cells to treat diseases such as cancer.

The present invention relates to a chimeric protein of IL-2 protein and IL-15 protein, a variant thereof, a fusion protein comprising the same, and / or a genetically engineered cell modified to express any one or more thereof. In the present invention, the binding to IL-2Rβ is weakened, the side effects caused by the excessive immune cell activity of IL-2 can be inhibited, and the rapid exhaustion of natural killer cells is prevented, thereby allowing the appropriate level of cell activity and cell survival ability to be maintained for a long time. Accordingly, the present invention can be used for modulating the immune system and treating immune-related diseases, such as cancer, infectious diseases, and autoimmune diseases.

The invention provides a pluripotent stem cell embryoid differentiation method and a culture medium thereof, and belongs to the technical field of cell culture. The inhibitors (Chroman 1 and Emricasan) of two signal paths are added into the basic culture medium, so that the differentiation of the pluripotent stem cells to embryoid bodies (EB) can be promoted, the cells can keep a good state in the preparation and differentiation process, and the cell survival rate is improved. Compared with a traditional hanging drop method, a microwell plate method and a centrifugal method for preparing EB, the pluripotent stem cell embryoid body differentiation method provided by the invention is simpler and easy in process amplification, exogenous factors and serum are not involved in the whole process, target cells can be produced in a large scale while the clinical application safety is ensured, and the method is suitable for industrial production. And a good technical support is provided for clinical application of the pluripotent stem cell embryoid body and the germ layer cells thereof.

Infarction damage is ameliorated or treated through the administration of a mitochondrial degradation inhibitor, such as one that acts by inhibiting translocation of one or more molecules across a mitochondrial membrane, for example BAX / BNIP3 complexes involved in mitochondrial degradation. By preventing mitochondrial degradation, one allows more efficient oxygenation of an infarcted region, allowing for a greater degree of cell survival and a more successful recovery.

The invention belongs to the technical field of medicines, and discloses application of Dcdc2b in preparation of a medicine for preventing or treating amyotrophic lateral sclerosis. Compared with a control cell pCI, the transcriptional level and the protein level of the Dcdc2b are remarkably reduced in a TDP43M337V cell. The Dcdc2b with low expression in the TDP43M337V cells can reduce the survival of the cells, so that the number of synapses of the cells is reduced, and the Dcdc2b is prompted to reduce the survival of the TDP43M337V cells by reducing the number of synapses.

The invention discloses a method for designing a bionic femoral stent based on fusion of a lattice structure and a TPMS structure, and belongs to the technical field of bionic bone stents. The method comprises the following steps: respectively creating a Diamond unit homogeneous porous structure CAD model and an Iso Truss unit homogeneous porous structure CAD model; creating a Ramp fusion function, and fusing the homogeneous porous structure of the Diamond unit and the homogeneous porous structure of the Iso Truss unit to generate a preliminary ITD fusion CAD model; then fusing the preliminary ITD fusion CAD model and a newly established cylinder III by using a Boolean intersection instruction to form a final ITD fusion CAD model, and finally dividing a finite element simulation grid model and outputting an inp-format simulation model file; importing the simulation model file in the inp format into HyperMesh software for repairing, and dividing grids to export the model in the inp file format. The bionic bone scaffold designed by the invention has higher bearing capacity and stability, and the formed mechanical property gradient adapts to a complex mechanical environment. Meanwhile, cell adhesion, proliferation and differentiation can be promoted, nutrient substances can be transported, metabolic waste can be discharged, and the cell survival rate can be increased.

The invention relates to the technical field of medical engineering, in particular to an NK cell delivery data processing method and system based on magnetic targeting. The method comprises the following steps: inquiring an immune receptor protein structure of natural killer cells; injecting a sodium chloride solution, adding an immune receptor protein structure, and reacting to generate an aptamer structure; the method comprises the following steps: combining streptavidin in a pre-prepared glycosyl magnetic microsphere to obtain a high-affinity magnetic bead; carrying out molecular docking on the high-affinity magnetic beads and the aptamer structure, recording a docking score, and generating an optimized aptamer; recording the magnetic bead mass ratio of the optimized aptamer; capturing the natural killer cells by adopting the optimized aptamer, and shooting to obtain a fluorescent microscopic image; and recording the dyeing condition of the fluorescent microscopic image, determining the survival state of the NK cells, marking the position information of the living cells, and generating an NK cell delivery efficiency table by using the mass ratio of the magnetic beads. Based on a medical engineering technology, the homing rate and the delivery efficiency of the NK cells at the liver injury part are improved.

The present invention provides a method, terminal and medium for obtaining a relative total biological effect value based on a boron neutron reaction. The method comprises obtaining a cell survival fraction model and a reference model corresponding to each target depth; obtaining, for each target depth, a mixed absorbed dose and a reference absorbed dose corresponding to the cell survival fraction to be measured according to the cell survival fraction to be measured; and obtaining a relative total biological effect value of the mixed absorbed dose at the corresponding target depth based on the mixed absorbed dose and the reference absorbed dose corresponding to each target depth. The present invention improves the accuracy of obtaining the cell survival fraction model while effectively improving the accuracy of obtaining the relative total biological effect value.

The present disclosure relates to the field of drug discovery and therapeutics, including systems and methods to predict drug function, to classify or prioritize drugs based on predicted function, and to test known and novel compounds for function in a vertebrate system. The present disclosure also relates to compounds identified using the disclosed systems and methods, the novel mechanisms of action of the compounds, and applications of the compounds as therapeutics, e.g., as cancer therapeutics.

This invention relates to the field of gene vector technology, and more particularly to an ionizable comb-like polymer, its preparation method, and its applications. This comb-like polymer is a block polymer, comprising at least one block unit. Each block unit includes a first block, a second block, and a third block linked by covalent bonds. It exhibits high molecular flexibility and readily binds to nucleic acid-like substances to form polymer / nucleic acid complexes. Due to the presence of easily degradable intracellular glycosidic bonds in its structure, the polymer demonstrates high transfection efficiency. Furthermore, cell experiments show that the polymer / nucleic acid complex exhibits low toxicity to cells and significantly improves cell survival compared to the positive control. Therefore, it holds promise for widespread application in cell transfection. The preparation method provided by this invention utilizes a redox amination tandem reaction to directly prepare the target product, eliminating the need for intermediate product purification processes. This simple process facilitates large-scale production.

The present invention discloses a method for enhancing the differentiation efficiency and survival duration of type I classical dendritic cells; during the induction process, by introducing the gene mycn, the present invention achieves a dual improvement in the induction efficiency of cDC1 and the survival of cDC cells. Through a humanized mouse tumor model, the greater effectiveness of the obtained mycn transgenic cDC1 for tumor treatment is verified.

This disclosure provides methods and compositions for genetically modifying lymphocytes, such as T cells and / or NK cells. [Solution] In some embodiments, the method comprises a reaction mixture produced using whole blood or its components other than PBMCs, and further comprising T cells and recombinant retroviral particles having polynucleotides encoding CARs, as well as the resulting cell preparation. In some embodiments, the modified lymphocytes are reintroduced subcutaneously into the subject. In some embodiments, polynucleotides are provided that confer to the T cells the ability to regulate cell survival and proliferation in response to binding to CARs.

Infarction damage is ameliorated or treated through the administration of a mitochondrial degradation inhibitor, such as one that acts by inhibiting translocation of one or more molecules across a mitochondrial membrane, for example BAX / BNIP3 complexes involved in mitochondrial degradation. By preventing mitochondrial degradation, one allows more efficient oxygenation of an infarcted region, allowing for a greater degree of cell survival and a more successful recovery.

Disclosed are compositions and methods related to RNA interference (RNAi) and the use of RNAi active sequence for treating diseases and disorders. Particular disclosed are toxic RNAi active sequences such as siRNA and shRNA for killing cancer cells. The disclosed toxic RNAi active sequences typically include trinucleotide repeats and preferentially target the expression of multiple essential genes for cell survival and / or growth.

Disclosed herein are stable live-cell compositions comprising a plurality of spheroids derived from neural progenitor cells and methods of making the spheroids. Also disclosed herein are methods of treating a neuronal disorder or disease.

The present invention provides a cell composition for treating detrusor underactivity and a method for preparing the same. The cell composition comprises a cell spheroid formed by seeding a plurality of mesenchymal stem cells in a culture device comprising a plurality of culture wells, wherein each of the culture wells has a surface coated with a low-protein-adhesion layer, and culturing the cells under the conditions to induce spheroid formation. Through the cell composition of the present invention, three-dimensional structured cell spheroids are formed to promote intercellular interactions and physiological function expression, thereby enhancing cell survival rates and functional performance after transplantation. In particular, the cell composition effectively facilitates the repair and restoration of contractile function of bladder muscle tissue, thereby improving the clinical symptoms associated with detrusor underactivity.

The invention discloses a sensitizing drug for resisting breast cancer by radiotherapy and a screening method and application thereof, and belongs to the field of biomedicine.The method comprises the steps that an in-vitro radiotherapy resistance model is constructed, a clinical segmentation radiotherapy dose increasing mode is simulated, stable acquired radiotherapy resistance is induced to be generated, and a carrier is provided for drug screening; natural plant small molecule compounds are used for treatment, and through concentration and time gradient dual control, the reversion ability of the natural plant small molecule compounds to radiotherapy resistance phenotypes is investigated; a multi-dimensional joint detection system is established, multi-level comprehensive evaluation is performed from cell survival and the like, the limitation of a single index is broken through, and the screening accuracy and reliability are improved; dNA damage repair is dynamically monitored through immunofluorescence, comet electrophoresis and the like, and the drug action mechanism is revealed. The medicine screened by the method is suitable for primary and acquired radiotherapy resistance patients, can effectively improve the radiotherapy curative effect, provides a new medicine source and scheme for clinical problems, and opens up the application of the compound in preparation of radiosensitizers or adjuvant therapy medicines.

The present invention relates to a butylphthalide dimer and a preparation method and application thereof, and the structural formula thereof is as follows: The present invention isolates butylphthalide dimer enantiomers from Lycopodiella vulgaris. The neuroprotective effect of the compound of the present invention is evaluated in a glutamate-induced neuronal cell HT-22 injury model. In particular, (-)-(6S,7R,6'R,7'S)-lycocasuarolide B(-)-2 exhibits significant neuroprotective activity in the model. At concentrations of 5μM, 10μM, 15μM, and 20μM, the cell survival rates are increased by 29.3%, 25.45%, 21.96%, and 21.57%, respectively, which is equivalent to the activity of the positive control drug 3-n-Butylphthalide. Compound (-)-2 can alleviate glutamate-induced neuronal cell death by inhibiting the apoptosis pathway.